Moderna expects vaccine sales to plummet 72.8% in 2023 + 4 updates

Moderna's revenue from its COVID-19 vaccine is expected to drop 72.8 percent, from $18.4 billion to a minimum of $5 billion, from 2022 to 2023's annual sales, the company said Jan. 9. 

Here are four other recent updates from the vaccine-maker: 

1. The company has 48 programs in development, including 36 in ongoing clinical studies. 

2. It projects spending $4.5 billion in 2023 on research and development. 

3. On Jan. 4, the company said it would acquire genomics company OriCiro for $85 million. 

4. Moderna will collaborate with an oncology business to investigate potential therapeutic options for mRNA, the technology used in its COVID-19 vaccine. 


Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars